(R) Chosa Oncology announces the result of exercise of warrants TO2

Read more

(R) CHOSA Oncology meddelar utfallet av utnyttjandet av teckningsoptioner av serie TO2

Read more

(R) Members of executive management participate in the ongoing warrant - exercise ending tomorrow

Read more

(R) Ledningsgruppen deltar i den pågående utnyttjandeperioden för teckningsoptioner som avslutas i morgon

Read more

(R) CHOSA Oncology appoints US commercialization Bill Cronin with a broad network in the oncology market, to accelerate launch of Platin-DRP

Read more

(R) CHOSA utser Bill Cronin, med ett bred erfarenhet av onkologimarknaden, att leda den amerikanska kommersialiseringen för att accelerera lanseringen av Platin-DRP

Read more

(R) CHOSA Oncology announces commencement of exercise period for TO2 warrants at the fixed price of SEK 0.78

Read more

(R) CHOSA Oncology meddelar att teckningsperioden för TO2-teckningsoptioner inleds till det fastställda lösenpriset om 0,78 SEK

Read more

CHOSA Oncology establishes US presence in Boston to support commercialization of Platin-DRP

Read more

CHOSA Oncology etablerar närvaro i USA för att stödja kommersialiseringen av Platin-DRP

Read more

(R) CHOSA presents data at ASCO validating Platin-DRP on the NanoString platform showing significant overall survival prediction in Phase III lung cancer study

Read more

(R) CHOSA and AIDA present data at ASCO 2026 showing up to 78% pathological complete response (pCR) rate in breast cancer using combined, integrated, taxane and platinum biomarkers

Read more